文献速递白血病淋巴瘤

IKAROS与CK2调控高危B细胞急性淋巴细胞白血病中BCL-XL的表达及化疗敏感性

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2020-01-01

高危B细胞急性淋巴细胞白血病(B-ALL)常对化疗耐药,IKAROS(由IKZF1编码)功能缺失是常见特征。本研究发现IKAROS通过结合BCL2L1启动子并招募HDAC1抑制BCL-XL表达,而CK2磷酸化IKAROS削弱该抑制,导致BCL-XL升高和多柔比星耐药;CK2抑制剂CX-4945可增强IKAROS结合、恢复对多柔比星的敏感性并在体外及临床前模型中显示协同效应。

要点

  • IKAROS结合BCL2L1启动子并招募HDAC1,通过染色质重塑抑制BCL-XL表达。
  • CK2磷酸化IKAROS减少其与BCL2L1启动子结合及HDAC1招募,使BCL-XL表达升高。
  • CX-4945抑制CK2可增强IKAROS对BCL2L1的抑制,并在体外及临床前模型中与多柔比星协同。

核心结论

  • IKAROS与CK2调控BCL2L1/BCL-XL表达,构成影响白血病化疗耐药的新信号网络。
  • CK2抑制剂CX-4945联合多柔比星在体外及高危B-ALL临床前模型中显示协同治疗效应。
  • 上述数据为CK2抑制剂CX-4945联合多柔比星用于血液系统恶性肿瘤的临床测试奠定基础。

研究设计与样本

  • 研究采用功能获得与功能缺失实验,在人B-ALL中分析IKAROS对BCL2L1的调控。
  • 研究使用CK2特异性抑制剂CX-4945进行分子与药理学抑制实验。
  • 研究在体外及高危B-ALL临床前模型中评估CX-4945与多柔比星联合治疗。

主要发现

  • 功能获得与功能缺失实验显示IKAROS结合BCL2L1启动子、招募HDAC1并经染色质重塑抑制BCL2L1表达。
  • CK2磷酸化降低IKAROS与BCL2L1启动子结合及HDAC1招募,导致IKAROS介导的BCL2L1抑制丧失、BCL-XL表达升高。
  • BCL-XL和/或CK2表达升高以及IKAROS表达降低与多柔比星治疗耐药相关。
  • CX-4945增加IKAROS与BCL2L1启动子结合并增强IKAROS介导的BCL2L1抑制。
  • CX-4945增加B-ALL对多柔比星的敏感性,并逆转多药耐药B-ALL对多柔比星的耐药。

临床怎么用

  • 作者认为上述数据为合理设计的靶向治疗临床测试奠定基础,该治疗将CK2抑制剂CX-4945与多柔比星联合用于血液系统恶性肿瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-risk B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive disease, often characterized by resistance to chemotherapy. A frequent feature of high-risk B-ALL is loss of function of the IKAROS (encoded by the IKZF1 gene) tumor suppressor. Here, we report that IKAROS regulates expression of the BCL2L1 gene (encodes the BCL-XL protein) in human B-ALL. Gain-of-function and loss-of-function experiments demonstrate that IKAROS binds to the BCL2L1 promoter, recruits histone deacetylase HDAC1, and represses BCL2L1 expression via chromatin remodeling. In leukemia, IKAROS' function is impaired by oncogenic casein kinase II (CK2), which is overexpressed in B-ALL. Phosphorylation by CK2 reduces IKAROS binding and recruitment of HDAC1 to the BCL2L1 promoter. This results in a loss of IKAROS-mediated repression of BCL2L1 and increased expression of BCL-XL. Increased expression of BCL-XL and/or CK2, as well as reduced IKAROS expression, are associated with resistance to doxorubicin treatment. Molecular and pharmacological inhibition of CK2 with a specific inhibitor CX-4945, increases binding of IKAROS to the BCL2L1 promoter and enhances IKAROS-mediated repression of BCL2L1 in B-ALL. Treatment with CX-4945 increases sensitivity to doxorubicin in B-ALL, and reverses resistance to doxorubicin in multidrug-resistant B-ALL. Combination treatment with CX-4945 and doxorubicin show synergistic therapeutic effects in vitro and in preclinical models of high-risk B-ALL. Results reveal a novel signaling network that regulates chemoresistance in leukemia. These data lay the groundwork for clinical testing of a rationally designed, targeted therapy that combines the CK2 inhibitor, CX-4945, with doxorubicin for the treatment of hematopoietic malignancies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Song C, Ge Z, Ding Y, et al. IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. Blood. 2020. PMID: 32396934. doi:10.1182/blood.2019002655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。